Medical Technology

Current search: " alnylam pharmaceuticals "

@xconomy.com 4 years ago

Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More

@xconomy.com 4 years ago

Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B

@xconomy.com 4 years ago

Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug

@xconomy.com 4 years ago

MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests

@xconomy.com 4 years ago

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

@xconomy.com 4 years ago

MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms

@xconomy.com 5 years ago

Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More

@xconomy.com 5 years ago

Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline

@xconomy.com 5 years ago

Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel

@xconomy.com 5 years ago

Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug

@xconomy.com 5 years ago

With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug

@xconomy.com 5 years ago

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

@xconomy.com 5 years ago

Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

@xconomy.com 5 years ago

Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More

@xconomy.com 5 years ago

Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision

@xconomy.com 5 years ago

CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”